Maintained activity of glycogen synthase kinase-3β despite of its phosphorylation at serine-9 in okadaic acid-induced neurodegenerative model

Biochemical and Biophysical Research Communications

Volumn 395, Issue 2, 2010, Pages 207-212

  Lim, Yong Whan ^a   Yoon, Seung Yong ^a   Choi, Jung Eun ^a   Kim, Sang Min ^a   Lee, Hui Sun ^a   Choe, Han ^a   Lee, Seung Chul ^b   Kim, Dong Hou ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b CrystalGenomics Inc   (South Korea)

Author keywords

Catenin; CRMP2; Drug discovery; GSK3 inhibitor

Indexed keywords

6 BROMOINDIRUBIN 3' MONOXIME; BETA CATENIN; COLLAPSIN RESPONSE MEDIATOR PROTEIN 2; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; KICG 1710; LITHIUM CHLORIDE; OKADAIC ACID; PHOSPHOPROTEIN PHOSPHATASE 2A; SERINE; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; CELL DEATH; CONTROLLED STUDY; DEGENERATIVE DISEASE; DRUG RESEARCH; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME SUBSTRATE; EXPERIMENTAL MODEL; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT;

ALZHEIMER DISEASE; ANIMALS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; GLYCOGEN SYNTHASE KINASE 3; INDOLES; LITHIUM CHLORIDE; NEURONS; OKADAIC ACID; OXIMES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN PHOSPHATASE 2; RATS; SERINE;

RATTUS;

EID: 77951623547     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.03.163     Document Type: Article

References (43)

1. Iqbal K., and Grundke-Iqbal I. Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention. J. Cell. Mol. Med. 12 (2008) 38-55
2. Lu P.J., Wulf G., Zhou X.Z., Davies P., and Lu K.P. The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein. Nature 399 (1999) 784-788
3. Gong C.X., Grundke-Iqbal I., and Iqbal K. Dephosphorylation of Alzheimer's disease abnormally phosphorylated tau by protein phosphatase-2A. Neuroscience 61 (1994) 765-772
4. Ferrer I., Barrachina M., and Puig B. Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Acta Neuropathol. 104 (2002) 583-591
5. Pei J.J., Braak E., Braak H., Grundke-Iqbal I., Iqbal K., Winblad B., and Cowburn R.F. Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. J. Neuropathol. Exp. Neurol. 58 (1999) 1010-1019
6. Pei J.J., Tanaka T., Tung Y.C., Braak E., Iqbal K., and Grundke-Iqbal I. Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain. J. Neuropathol. Exp. Neurol. 56 (1997) 70-78
7. Yamaguchi H., Ishiguro K., Uchida T., Takashima A., Lemere C.A., and Imahori K. Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK) I/glycogen synthase kinase-3 beta and cyclin-dependent kinase 5, a component of TPK II. Acta Neuropathol. 92 (1996) 232-241
8. Drewes G., Lichtenberg-Kraag B., Doring F., Mandelkow E.M., Biernat J., Goris J., Doree M., and Mandelkow E. Mitogen activated protein (MAP) kinase transforms tau protein into an Alzheimer-like state. EMBO J. 11 (1992) 2131-2138
9. Baumann K., Mandelkow E.M., Biernat J., Piwnica-Worms H., and Mandelkow E. Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5. FEBS Lett. 336 (1993) 417-424
10. Pei J.J., Grundke-Iqbal I., Iqbal K., Bogdanovic N., Winblad B., and Cowburn R.F. Accumulation of cyclin-dependent kinase 5 (cdk5) in neurons with early stages of Alzheimer's disease neurofibrillary degeneration. Brain Res. 797 (1998) 267-277
11. Zhu X., Ogawa O., Wang Y., Perry G., and Smith M.A. JKK1, an upstream activator of JNK/SAPK, is activated in Alzheimer's disease. J. Neurochem. 85 (2003) 87-93
12. Shoji M., Iwakami N., Takeuchi S., Waragai M., Suzuki M., Kanazawa I., Lippa C.F., Ono S., and Okazawa H. JNK activation is associated with intracellular beta-amyloid accumulation. Brain Res. Mol. Brain Res. 85 (2000) 221-233
13. Hooper C., Killick R., and Lovestone S. The GSK3 hypothesis of Alzheimer's disease. J. Neurochem. 104 (2008) 1433-1439
14. Ghanevati M., and Miller C.A. Phospho-beta-catenin accumulation in Alzheimer's disease and in aggresomes attributable to proteasome dysfunction. J. Mol. Neurosci. 25 (2005) 79-94
15. Gu Y., Hamajima N., and Ihara Y. Neurofibrillary tangle-associated collapsin response mediator protein-2 (CRMP-2) is highly phosphorylated on Thr-509, Ser-518, and Ser-522. Biochemistry 39 (2000) 4267-4275
16. Swatton J.E., Sellers L.A., Faull R.L., Holland A., Iritani S., and Bahn S. Increased MAP kinase activity in Alzheimer's and Down syndrome but not in schizophrenia human brain. Eur. J. Neurosci. 19 (2004) 2711-2719
17. Stambolic V., and Woodgett J.R. Mitogen inactivation of glycogen synthase kinase-3 beta in intact cells via serine 9 phosphorylation. Biochem. J. 303 Pt. 3 (1994) 701-704
18. Zhou X.W., Gustafsson J.A., Tanila H., Bjorkdahl C., Liu R., Winblad B., and Pei J.J. Tau hyperphosphorylation correlates with reduced methylation of protein phosphatase 2A. Neurobiol. Dis. 31 (2008) 386-394
19. Arias C., Sharma N., Davies P., and Shafit-Zagardo B. Okadaic acid induces early changes in microtubule-associated protein 2 and tau phosphorylation prior to neurodegeneration in cultured cortical neurons. J. Neurochem. 61 (1993) 673-682
20. Kim D., Su J., and Cotman C.W. Sequence of neurodegeneration and accumulation of phosphorylated tau in cultured neurons after okadaic acid treatment. Brain Res. 839 (1999) 253-262
21. Wang J., Tung Y.C., Wang Y., Li X.T., Iqbal K., and Grundke-Iqbal I. Hyperphosphorylation and accumulation of neurofilament proteins in Alzheimer disease brain and in okadaic acid-treated SY5Y cells. FEBS Lett. 507 (2001) 81-87
22. Pei J.J., Gong C.X., An W.L., Winblad B., Cowburn R.F., Grundke-Iqbal I., and Iqbal K. Okadaic-acid-induced inhibition of protein phosphatase 2A produces activation of mitogen-activated protein kinases ERK1/2, MEK1/2, and p70 S6, similar to that in Alzheimer's disease. Am. J. Pathol. 163 (2003) 845-858
23. Yoon S.Y., Choi J.E., Huh J.W., Hwang O., Nam Hong H., and Kim D. Inactivation of GSK-3beta in okadaic acid-induced neurodegeneration: relevance to Alzheimer's disease. Neuroreport 16 (2005) 223-227
24. D.C. Weiser, S. Shenolikar, Use of protein phosphatase inhibitors, Curr. Protoc. Protein Sci. Chapter 13 (2003) Unit 13.10.
25. Yoon S.Y., Choi J.E., Yoon J.H., Huh J.W., and Kim D.H. BACE inhibitor reduces APP-beta-C-terminal fragment accumulation in axonal swellings of okadaic acid-induced neurodegeneration. Neurobiol. Dis. 22 (2006) 435-444
26. Wang J.Z., Grundke-Iqbal I., and Iqbal K. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur. J. Neurosci. 25 (2007) 59-68
27. Liu C., Li Y., Semenov M., Han C., Baeg G.H., Tan Y., Zhang Z., Lin X., and He X. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 108 (2002) 837-847
28. Ni M.H., Wu C.C., Chan W.H., Chien K.Y., and Yu J.S. GSK-3 mediates the okadaic acid-induced modification of collapsin response mediator protein-2 in human SK-N-SH neuroblastoma cells. J. Cell. Biochem. 103 (2008) 1833-1848
29. Cole A.R., Causeret F., Yadirgi G., Hastie C.J., McLauchlan H., McManus E.J., Hernandez F., Eickholt B.J., Nikolic M., and Sutherland C. Distinct priming kinases contribute to differential regulation of collapsin response mediator proteins by glycogen synthase kinase-3 in vivo. J. Biol. Chem. 281 (2006) 16591-16598
30. Rayasam G.V., Tulasi V.K., Sodhi R., Davis J.A., and Ray A. Glycogen synthase kinase 3: more than a namesake. Br. J. Pharmacol. 156 (2009) 885-898
31. Komiya Y., and Habas R. Wnt signal transduction pathways. Organogenesis 4 (2008) 68-75
32. Lee K.S., Seo S.H., Lee Y.H., Kim H.D., Son M.H., Chung B.Y., Lee J.Y., Jin C., and Lee Y.S. Synthesis and biological evaluation of chromone carboxamides as calpain inhibitors. Bioorg. Med. Chem. Lett. 15 (2005) 2857-2860
33. Bretin S., Rogemond V., Marin P., Maus M., Torrens Y., Honnorat J., Glowinski J., Premont J., and Gauchy C. Calpain product of WT-CRMP2 reduces the amount of surface NR2B NMDA receptor subunit. J. Neurochem. 98 (2006) 1252-1265
34. Yoon S., Choi J., Huh J.W., Hwang O., and Kim D. Calpain activation in okadaic-acid-induced neurodegeneration. Neuroreport 17 (2006) 689-692
35. Bain J., Plater L., Elliott M., Shpiro N., Hastie C.J., McLauchlan H., Klevernic I., Arthur J.S., Alessi D.R., and Cohen P. The selectivity of protein kinase inhibitors: a further update. Biochem. J. 408 (2007) 297-315
36. Pei J.J., Khatoon S., An W.L., Nordlinder M., Tanaka T., Braak H., Tsujio I., Takeda M., Alafuzoff I., Winblad B., Cowburn R.F., Grundke-Iqbal I., and Iqbal K. Role of protein kinase B in Alzheimer's neurofibrillary pathology. Acta Neuropathol. 105 (2003) 381-392
37. Liang J., and Slingerland J.M. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2 (2003) 339-345
38. Boonen R.A., van Tijn P., and Zivkovic D. Wnt signaling in Alzheimer's disease: up or down, that is the question. Ageing Res. Rev. 8 (2009) 71-82
39. Drees F., Pokutta S., Yamada S., Nelson W.J., and Weis W.I. Alpha-catenin is a molecular switch that binds E-cadherin-beta-catenin and regulates actin-filament assembly. Cell 123 (2005) 903-915
40. Cole A.R., Noble W., van Aalten L., Plattner F., Meimaridou R., Hogan D., Taylor M., LaFrancois J., Gunn-Moore F., Verkhratsky A., Oddo S., LaFerla F., Giese K.P., Dineley K.T., Duff K., Richardson J.C., Yan S.D., Hanger D.P., Allan S.M., and Sutherland C. Collapsin response mediator protein-2 hyperphosphorylation is an early event in Alzheimer's disease progression. J. Neurochem. 103 (2007) 1132-1144
41. Chae Y.C., Lee S., Heo K., Ha S.H., Jung Y., Kim J.H., Ihara Y., Suh P.G., and Ryu S.H. Collapsin response mediator protein-2 regulates neurite formation by modulating tubulin GTPase activity. Cell. Signal. 21 (2009) 1818-1826
42. Brown M., Jacobs T., Eickholt B., Ferrari G., Teo M., Monfries C., Qi R.Z., Leung T., Lim L., and Hall C. Alpha2-chimaerin, cyclin-dependent Kinase 5/p35, and its target collapsin response mediator protein-2 are essential components in semaphorin 3A-induced growth-cone collapse. J. Neurosci. 24 (2004) 8994-9004
43. Uchida Y., Ohshima T., Sasaki Y., Suzuki H., Yanai S., Yamashita N., Nakamura F., Takei K., Ihara Y., Mikoshiba K., Kolattukudy P., Honnorat J., and Goshima Y. Semaphorin3A signalling is mediated via sequential Cdk5 and GSK3beta phosphorylation of CRMP2: implication of common phosphorylating mechanism underlying axon guidance and Alzheimer's disease. Genes Cells 10 (2005) 165-179